|
Chairman, Chief Executive Officer and President,
Telik, Inc.
Former Vice President of Operations, Lederle
Laboratories
Former Vice Chairman and Chief Financial Officer,
Bank of America
Chief Scientific Officer - Research Administration, Hospital for Special Surgery
President, Gray Strategic Advisors, LLC
President and Chief Executive Officer, D&R
Products Co., Inc.
Managing Director, Bear Stearns Health Innoventures
Chairman, Chief Executive Officer and President,
Telik, Inc.
Michael M. Wick, M.D., Ph.D. is Chairman and Chief Executive Officer of Telik, Inc. (Nasdaq: TELK).
He joined Telik in 1997 from CV Therapeutics, Inc. where he was Senior Vice President of Research and Development.
Prior to joining CV Therapeutics, Dr. Wick was Executive Director of Oncology/Immunology and Clinical Research
at Lederle Laboratories, a division of American Cyanamid, where he also directed the Cyanamid/Immunex joint
oncology research program. Dr. Wick began his career at Harvard Medical School, where he was an Associate
Professor. He also was Chief of the Melanoma Clinic and Laboratory of Molecular Dermatological Oncology at
the Dana Farber Cancer Institute. Dr. Wick holds a Ph.D. in chemistry from Harvard University and an M.D.
from Harvard Medical School.
Top
Former Vice President of Operations, Lederle
Laboratories
Dr. Cantrall, a consultant to biotechnology and genomics companies, joined our Board of
Directors in May 2002. He serves on the Board's audit committee. He was Vice President
of Operations at Lederle Laboratories, a division of American Cyanamid Company subsequently
acquired by Wyeth. His fields of expertise include pharmaceutical development and manufacturing.
Dr. Cantrall holds a Ph.D. degree in organic chemistry from the University of Illinois and an M.B.A.
degree in industrial management from Fairleigh Dickinson University.
Top
Former Vice Chairman and Chief Financial Officer,
Bank of America
Robert W. Frick has served as one of Telik's directors since April 2003.
He serves on the Board's audit committee. From 1976 until his retirement in 1998, Mr. Frick
served in various capacities at Bank of America, including Vice Chairman of the Board and
Chief Financial Officer. Mr. Frick currently serves on the Board of Directors of several private
companies. He is currently an adjunct professor of business strategy in the graduate business
program at St. Mary's College. He holds a B.S. in civil engineering and an M.B.A. from Washington
University, St. Louis.
Top
Chief Scientific Officer - Research Administration, Hospital for Special Surgery
Dr. Goldring joined our Board of Directors in May 2002. He serves on the Board's
compensation committee. A highly experienced clinical research leader, he is a Chief Scientific Officer -
Research Administration, Hospital for Special Surgery. Previously he was a Professor of
Medicine at Harvard Medical School and Chief of Rheumatology at Beth Israel Deaconess Medical Center.
He has also served as the Director of the New England Baptist Bone and Joint Institute. Dr. Goldring has
served as a consultant or Principal Investigator for pharmaceutical industry, foundation and
NIH-sponsored research programs, and as a consultant to numerous pharmaceutical and biotechnology
companies. Dr. Goldring received his medical training at Peter Bent Brigham Hospital and Massachusetts
General Hospital. He holds an M.D. degree from the Washington University School of Medicine.
Top
President, Gray Strategic Advisors, LLC
Mary Ann Gray, Ph.D. joined the Telik Board of Directors in August 2003.
She is a member of the Board's nominating committee. Dr. Gray is President of Gray
Strategic Advisors, LLC and serves on the Board of Directors of Dyax Corporation.
Dr. Gray was a senior analyst and portfolio manager for the Federated Kaufmann Fund,
and previously led biotechnology equity research groups at Raymond James & Associates,
Warburg Dillon Read and Kidder Peabody. Dr. Gray holds a Ph.D. in pharmacology from the
University of Vermont.
Top
President and Chief Executive Officer, D&R
Products Co., Inc.
Richard B. Newman has served as a director of Telik since April 2003. He serves
on the Board's compensation committee. Since 1983, Mr. Newman is President and
Chief Executive Officer of D&R Products Co., Inc., which designs, develops and manufactures
orthopedic, vascular and other surgical medical devices and instruments for major medical device
and instrument manufacturers in the U.S. and Europe. He has extensive experience in acquiring and
operating industrial, real estate and software businesses. Mr. Newman holds an A.B. from Harvard
College and a LL.B. from Harvard Law School.
Top
Managing Director, Bear Stearns Health Innoventures
Dr. Ryser has served as one of our directors since September 1998. He serves on the Board's
compensation committee. Since April 2000, Dr. Ryser has served as a managing director of Bear
Stearns Health Innoventures, a venture capital fund. Dr. Ryser served as Chief Executive Officer
until April 2000, and has served as a member and delegate of the board of International Biomedicine
Management Partners Inc. From January 1989 until 1997, Dr. Ryser held various positions at Roche,
including Scientific Assistant to the President of Global Research and Development, and was
responsible for maintaining the scientific liaison between Roche and Genentech. Dr. Ryser
received a Ph.D. degree in molecular biology from the University of Basel.
Top
Dr. von Morzé joined the Telik Board of Directors in August 2004. He is an international
consultant specializing in pharmaceutical patent strategy, patent prosecution and pharmaceutical
product life cycle management. Dr. von Morzé most recently was Co-Chair of Heller Ehrman's
Patent and Trademark Practice Group. He has directed patent prosecution and enforcement programs
in the pharmaceutical industry for more than 25 years.
Top
|
